CLINICAL_TRIALS trial_result · 2016-02-24

Clinical Trial Update: PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers [Phase 1]

Phase 1 PK/PD study of emricasan (IDN-6556) in subjects with hepatic impairment and matched healthy volunteers has completed; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Hepatic Impairment, Liver Diseases | Phase 1 | Status: COMPLETED | Results posted: 2016-02-24